Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus
Round 1
Reviewer 1 Report
The manuscript is very interesting and well structured. I recommend its publication in the present form.
I just suggest performing extensive editing of the English language and style.
Author Response
Thank you very much for your valuable comments We do believe that they contribute significantly to improvement of quality of our manuscript
As You proposed we added table that summarises recent trials in SLE and SSc.
Many thanks for finding typo errors they were corrected as follow:
Row 30 “…is to reduce of… changed to The final result of this immunosuppression is reduction of
Row 50 in treatment in many…”(typo) changed to efficacious in treatment of many
Row 55 “….biologics is sometimes infective….”(please clarify) we changed to is sometimes clinically infective
Row 58 check punctuation punctuation corrected
Row 108 “…. propagation ….”(please clarify) word propagation removed The current sentence sounds like cytokines plays an unequivocal role in the development of several CTDs
Row 160 check punctuation punctuation corrected
Row 205 “…Less in known….” (typo) we wrote less is known
Rows 231-232 check punctuation and repetition of words we rewrote to systemic sclerosis is still a condition where no disease-specific treatment exists.
Row 307 ” ….corelated…”(typo) changed to correlated
Row 316 “….vide…..”(typo) corrected to wide
Row 342 “…corelate …”(typo) corrected to correlate
Row 405 “….a key role seems to be…(please check the verb and the sentence) We wrote It is plausible that inhibition of IL-6 signalling that is realized by inhibition of Jak kinase attached to an IL-6 receptor may play the role in this process.
Row 410 check punctuation punctuation corrected
Rows 438-439 check the sentence (“but not these…” )and block letters for IL-12 and IL-23 capaiatl letters used additionally we wrote Filgotinib is a JAK1 specific inhibitor targeting almost all SLE-cytokine related receptors, but it is not able to stop signalling of IL-12/IL-23, IL3 and IL-5. Blocking IL12/IL-23
Author Response File: 
Author Response.docx
Reviewer 2 Report
This review explore in depth JAK Kinase cytokines network and its role in Systemic Sclerosis (SSc) and in Systemic Lupus Eritematosus (SLE) providing a potential rationale for the use of JAK-Inihibitors.
The use of these drugs , approved for Rheumatoid Arthritis (RA) and Psoriasic Arthritis (PsA), is one of the hottest topics in Rheumatology. Exploring new potential targets for the treatment of severe diseases such as SSc and SLE it’s extremely important.
The authors describe in a clear and detailed manner the JAK Kinase structure and functions and its potential involvement in SSc and SLE pathogenesis for every single cytokines.
My suggestions for the author are:
1. Briefly describe JAK-inhibitors family (authors just mention their name describing some studies)
2. Check language, grammar and punctuation in the whole review. There are some typos in the text. In particular I point out:
· Row 30 “…is to reduce of…”(typo)
· Row 50 “…in treatment in many…”(typo)
· Row 55 “….biologics is sometimes infective….”(please clarify)
· Row 58 check punctuation
· Row 108 “…. propagation ….”(please clarify)
· Row 160 check punctuation
· Row 205 “…Less in known….” (typo)
· Rows 231-232 check punctuation and repetition of words
· Row 307 ” ….corelated…”(typo)
· Row 316 “….vide…..”(typo)
· Row 342 “…corelate …”(typo)
· Row 405 “….a key role seems to be…(please check the verb and the sentence)
· Row 410 check punctuation
· Rows 438-439 check the sentence (“but not these…” )and block letters for IL-12 and IL-23
Author Response
Thank you very much for your review
The paper has been checked again by Dr Laura Coates Professor of Oxford University UK as it was stated in acknowledgements part of the paper
Additionally we corrected some typos and checked punctuation
